These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

99 related items for PubMed ID: 9664779

  • 1. Transient psychosis with psychogenic polydipsia in schizotypal patient taking fluoxetine.
    Gutkovich Z, Rosenthal RN, Bogdonoff L.
    Psychosomatics; 1998; 39(3):295-6. PubMed ID: 9664779
    [No Abstract] [Full Text] [Related]

  • 2. Fluoxetine-induced mania in an Asian patient.
    Pae CU, Lee CU, Lee SJ, Lee C, Paik IH.
    Psychiatry Clin Neurosci; 2004 Aug; 58(4):448-9. PubMed ID: 15298662
    [No Abstract] [Full Text] [Related]

  • 3. Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse.
    Iovieno N, van Nieuwenhuizen A, Clain A, Baer L, Nierenberg AA.
    Depress Anxiety; 2011 Feb; 28(2):137-44. PubMed ID: 21284066
    [Abstract] [Full Text] [Related]

  • 4. Ecchymoses as an adverse effect of fluoxetine treatment.
    Fountoulakis KN, Samolis S, Iacovides A, St Kaprinis G.
    Psychiatry Res; 2007 Jul 30; 152(1):91-2. PubMed ID: 17445912
    [Abstract] [Full Text] [Related]

  • 5. Double-blind randomized parallel-group clinical trial of efficacy of the combination fluoxetine plus modafinil versus fluoxetine plus placebo in the treatment of major depression.
    Abolfazli R, Hosseini M, Ghanizadeh A, Ghaleiha A, Tabrizi M, Raznahan M, Golalizadeh M, Akhondzadeh S.
    Depress Anxiety; 2011 Apr 30; 28(4):297-302. PubMed ID: 21456039
    [Abstract] [Full Text] [Related]

  • 6. Fluoxetine associated with thrombocytopenia and treatment with reboxetine: 3 cases.
    Yucel A, Yucel N, Ozcan H, Gulec M, Aydin A.
    J Clin Psychopharmacol; 2015 Jun 30; 35(3):354-5. PubMed ID: 25822478
    [No Abstract] [Full Text] [Related]

  • 7. The role of clinical variables, neuropsychological performance and SLC6A4 and COMT gene polymorphisms on the prediction of early response to fluoxetine in major depressive disorder.
    Gudayol-Ferré E, Herrera-Guzmán I, Camarena B, Cortés-Penagos C, Herrera-Abarca JE, Martínez-Medina P, Cruz D, Hernández S, Genis A, Carrillo-Guerrero MY, Avilés Reyes R, Guàrdia-Olmos J.
    J Affect Disord; 2010 Dec 30; 127(1-3):343-51. PubMed ID: 20584552
    [Abstract] [Full Text] [Related]

  • 8. A Case of Fluoxetine-Induced Lower Extremity Ecchymosis.
    Çetin B, Ergelen M.
    Prim Care Companion CNS Disord; 2017 Jun 15; 19(3):. PubMed ID: 28636812
    [No Abstract] [Full Text] [Related]

  • 9. Hopelessness as a predictor of non-response to fluoxetine in major depressive disorder.
    Papakostas GI, Petersen T, Homberger CH, Green CH, Smith J, Alpert JE, Fava M.
    Ann Clin Psychiatry; 2007 Jun 15; 19(1):5-8. PubMed ID: 17453655
    [Abstract] [Full Text] [Related]

  • 10. Paroxetine in a patient with obsessive-compulsive disorder, anorexia nervosa and schizotypal personality disorder.
    Heiden A, de Zwaan M, Frey R, Presslich O, Kasper S.
    J Psychiatry Neurosci; 1998 May 15; 23(3):179-80. PubMed ID: 9595892
    [No Abstract] [Full Text] [Related]

  • 11. Sexual functioning in patients with recurrent major depressive disorder enrolled in the PREVENT study.
    Gelenberg AJ, Dunner DL, Rothschild AJ, Pedersen R, Dorries KM, Ninan PT.
    J Nerv Ment Dis; 2013 Apr 15; 201(4):266-73. PubMed ID: 23538970
    [Abstract] [Full Text] [Related]

  • 12. Predictors of fluoxetine remission for hospitalized patients with major depressive disorder.
    Lin CH, Lane HY, Chen CC, Juo SH, Yen CF.
    Psychiatry Clin Neurosci; 2011 Aug 15; 65(5):510-7. PubMed ID: 21851460
    [Abstract] [Full Text] [Related]

  • 13. Fluoxetine versus trimipramine in the treatment of depression in geriatric patients.
    Wehmeier PM, Kluge M, Maras A, Riemann D, Berger M, Kohnen R, Dittmann RW, Gattaz WF.
    Pharmacopsychiatry; 2005 Jan 15; 38(1):13-6. PubMed ID: 15706460
    [Abstract] [Full Text] [Related]

  • 14. Low-dose-trazodone-induced disorganized type psychosis.
    Mizoguchi Y, Monji A.
    J Neuropsychiatry Clin Neurosci; 2005 Jan 15; 17(2):253-4. PubMed ID: 15939985
    [No Abstract] [Full Text] [Related]

  • 15. Oxidative stress parameters after combined fluoxetine and acetylsalicylic acid therapy in depressive patients.
    Gałecki P, Szemraj J, Bieńkiewicz M, Zboralski K, Gałecka E.
    Hum Psychopharmacol; 2009 Jun 15; 24(4):277-86. PubMed ID: 19319921
    [Abstract] [Full Text] [Related]

  • 16. Bupropion-induced psychosis.
    Howard WT, Warnock JK.
    Am J Psychiatry; 1999 Dec 15; 156(12):2017-8. PubMed ID: 10588428
    [No Abstract] [Full Text] [Related]

  • 17. Dysfunctional attitudes and perceived stress predict depressive symptoms severity following antidepressant treatment in patients with chronic depression.
    Pedrelli P, Feldman GC, Vorono S, Fava M, Petersen T.
    Psychiatry Res; 2008 Dec 15; 161(3):302-8. PubMed ID: 18976817
    [Abstract] [Full Text] [Related]

  • 18. Fluoxetine versus placebo in depressed alcoholics: a 1-year follow-up study.
    Cornelius JR, Salloum IM, Haskett RF, Daley DC, Cornelius MD, Thase ME, Perel JM.
    Addict Behav; 2000 Dec 15; 25(2):307-10. PubMed ID: 10795957
    [Abstract] [Full Text] [Related]

  • 19. Problem-solving ability and comorbid personality disorders in depressed outpatients.
    Harley R, Petersen T, Scalia M, Papakostas GI, Farabaugh A, Fava M.
    Depress Anxiety; 2006 Dec 15; 23(8):496-501. PubMed ID: 16845662
    [Abstract] [Full Text] [Related]

  • 20. Fluoxetine-induced SIADH: most likely in the elderly?
    Burke D, Franker S.
    Aust N Z J Psychiatry; 1996 Apr 15; 30(2):299-301. PubMed ID: 8811278
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.